A Novel Type of Influenza Vaccine: Safety and Immunogenicity of Replication‐Deficient Influenza Virus Created by Deletion of the Interferon Antagonist NS1
Volker Wacheck(Taiho Oncology (United States)), Thomas Muster(University of Vienna), Boris Ferko, Therese Popow‐Kraupp, Alexander Morokutti, Julia Romanova, Michael Bergmann(Comprehensive Cancer Center Vienna), Janina Geiler(Goethe University Frankfurt), Andrej Egorov, Jindřich Činátl(Goethe University Frankfurt), Elisabeth Roethl, Christian A. Mueller(Medical University of Vienna), Monika Redlberger‐Fritz(Medical University of Vienna), Martin Michaelis(University of Kent), Doris Hoeflmayer(Medical University of Vienna), Franz Groiss, Markus Wolschek, Joachim Seipelt, Andrea Pfeiffer, Thorsten Fuereder(Medical University of Vienna), Rosmarie Dick‐Gudenus, Michael Kundi(Medical University of Vienna)
Cited by 131
Related Papers
Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
|New England Journal of Medicine|2003|4.8k
Estimates of global seasonal influenza-associated respiratory mortality: a modelling study
|The Lancet|2017|3.1k
Use and acceptance of complementary and alternative medicine among the general population and medical personnel: a systematic review.
|PubMed|2012|531
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
EUROPAEM EMF Guideline 2016 for the prevention, diagnosis and treatment of EMF-related health problems and illnesses
|Reviews on Environmental Health|2016|496